Cover Image

Vitiligo during dupilumab therapy

Saved in:

Bibliographic Details
Main Authors:	Vincenzo Picone, MD (Author), Maddalena Napolitano, MD (Author), Ginevra Torta, MD (Author), Gabriella Fabbrocini, MD, PhD (Author), Cataldo Patruno, MD, PhD (Author)
Format:	Book
Published:	Elsevier, 2023-06-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Injection site reactions after dupilumab or tralokinumab for atopic dermatitis
by: Fabrizio Martora, et al.
Published: (2024)

Onychodystrophy associated with dupilumab therapy for atopic dermatitis
by: Amanda E. Zubek, MD, PhD, et al.
Published: (2021)

Exacerbation of IgA nephropathy in a patient receiving dupilumab
by: Masako Yamamoto, MD, et al.
Published: (2022)

Remission of severe atopic dermatitis with dupilumab and rescue tofacitinib therapy
by: Danielle M. Peterson, MD, et al.
Published: (2021)

Treatment of lichen sclerosus and hypertrophic scars with dupilumab
by: Danielle M. Peterson, MD, et al.
Published: (2022)

Treatment of Atopic Dermatitis with Biologic Drugs
by: Gabriella Fabbrocini, et al.
Published: (2018)

Recalcitrant bullous pemphigoid responsive to dupilumab in an adolescent patient
by: Albert E. Zhou, MD, PhD, et al.
Published: (2022)

Dupilumab as a novel steroid-sparing treatment for hypereosinophilic syndrome
by: Xiaoman Du, MD, et al.
Published: (2022)

Pembrolizumab-induced lichenoid dermatitis treated with dupilumab
by: Jonathan J. Park, PhD, et al.
Published: (2023)

Lethal anaplastic large-cell lymphoma occurring in a patient treated with dupilumab
by: Aurélie Du-Thanh, MD, PhD, et al.
Published: (2021)

Intravenous immunoglobulin-induced eczematous dermatitis treated with dupilumab
by: Katelyn Singh, MD, et al.
Published: (2024)

JAK-inhibitors as rescue therapy in dupilumab-refractory severe atopic dermatitis: A case series of 6 patients
by: Neda Shahriari, MD, et al.
Published: (2023)

Introduction of self-injection increases compliance with dupilumab administration in adult patients with atopic dermatitis: A single-center retrospective study
by: Makoto Ito, MD, et al.
Published: (2020)

Dupilumab as a therapy option for treatment refractory mogamulizumab-associated rash
by: Nicholas A. Trum, BS, et al.
Published: (2021)

Pemphigoid gestationis treated with dupilumab
by: Rita E. Chen, BA, et al.
Published: (2023)

De novo case of lichenoid eruption following dupilumab treatment
by: Tae-Eun Kim, MD, et al.
Published: (2021)

Prurigo nodularis in vitiligo patches: An unusual observation
by: Karim Saleh, MD, PhD
Published: (2020)

Analysis of tumor response and clinical factors associated with vitiligo in patients receiving anti-programmed cell death-1 therapies for melanoma: A cross-sectional studyCapsule Summary
by: Léa Dousset, MD, et al.
Published: (2021)

Pyoderma gangrenosum developing in a patient treated with dupilumab
by: Jessica Nasseh, MD, et al.
Published: (2022)

Dupilumab in HIV-positive patients: A case series report of 4 patients
by: Ameen Alawadhi, MD, et al.
Published: (2020)

Refractory eczematous dermatitis arising after allogeneic hematopoietic stem cell transplantation responsive to dupilumab
by: Jenny Lai, PhD, et al.
Published: (2024)

Vitiligo of the arm after COVID-19 vaccination
by: Rhea Singh, BS, et al.
Published: (2022)

Risk of skin cancer in patients with vitiligo in Denmark: A nationwide cohort studyCapsule Summary
by: Mads Gustaf Jørgensen, MD, et al.
Published: (2020)

Drug-induced interstitial lung disease associated with dupilumab for the treatment of atopic dermatitis
by: Bethany F. Wilken, MSc, et al.
Published: (2024)

Novel use of dupilumab in pemphigus vulgaris and pemphigus foliaceus
by: Christina Jiang, BS, MS, et al.
Published: (2023)

Resolution of dupilumab-associated alopecia areata with dosage modification
by: Maansi Kulkarni, BS, et al.
Published: (2022)

Dupilumab-induced erythema nodosum
by: Danielle E. Mustin, MEng, et al.
Published: (2022)

Hidradenitis suppurativa flares following COVID-19 vaccination: A case series
by: Fabrizio Martora, MD, et al.
Published: (2022)

Did dupilumab unmask smoldering mycosis fungoides?
by: Michelle Toker, BS, et al.
Published: (2023)

A retrospective multicenter case series of real-world tralokinumab use in dupilumab-experienced patients
by: Edward I. Herman, MD, PhD, et al.
Published: (2024)

Vitiligo associated with polycaprolactone-based collagen stimulator filler
by: Chun-Hsien Huang, MD, et al.
Published: (2022)

Pilocarpine as a treatment option for dupilumab-related eye manifestations
by: Won Seok Roh, MD, et al.
Published: (2022)

Estimating the burden of vitiligo: a systematic review and modelling study
by: Jennifer Akl, MD, et al.
Published: (2024)

A case report of uveitis secondary to dupilumab treatment for atopic dermatitis
by: Marissa Ayasse, BS, et al.
Published: (2021)

Vitiligo responds to topical aryl hydrocarbon receptor agonist tapinarof (WBI-1001)
by: Lisa Liu, BS, et al.
Published: (2023)

Refractory pruritus responds to dupilumab in a patient with TTC7A mutation
by: Yassaman Alipour Tehrany, MD, et al.
Published: (2021)

Excimer laser for the treatment of incomplete rerepigmentation 1 year after cultured epidermal autograft use for carbon dioxide laser-ablated lesions in patients with stable vitiligo
by: Hiroshi Kato, MD, PhD, et al.
Published: (2024)

Analyzing Fitzpatrick skin type distribution of vitiligo on Instagram
by: Britney T. Nguyen, BS, et al.
Published: (2024)

Vitiligo-like amelanotic melanoma in situ: A rare presentation
by: Lilia Maria Lima de Oliveira, MD, et al.
Published: (2024)

Incidental improvement of programmed cell death-1 receptor inhibitor-induced vitiligo after initiation of dupilumab therapy for refractory pruritus
by: Warner Robinson, DDS, et al.
Published: (2023)